Unanticipated increases in hepatic steatosis among human immunodeficiency virus patients receiving mineralocorticoid receptor antagonist eplerenone for non ‐alcoholic fatty liver disease
Liver International, EarlyView.
Source: Liver International - Category: Gastroenterology Source Type: research
More News: Alcoholism | Fatty Liver Disease (FLD) | Gastroenterology | Liver | Liver Disease | Urology & Nephrology